These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

930 related articles for article (PubMed ID: 8097319)

  • 1. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
    Dranoff G; Jaffee E; Lazenby A; Golumbek P; Levitsky H; Brose K; Jackson V; Hamada H; Pardoll D; Mulligan RC
    Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3539-43. PubMed ID: 8097319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
    Mach N; Gillessen S; Wilson SB; Sheehan C; Mihm M; Dranoff G
    Cancer Res; 2000 Jun; 60(12):3239-46. PubMed ID: 10866317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
    Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice.
    Nagai E; Ogawa T; Kielian T; Ikubo A; Suzuki T
    Cancer Immunol Immunother; 1998 Oct; 47(2):72-80. PubMed ID: 9769115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity.
    McLaughlin JP; Abrams S; Kantor J; Dobrzanski MJ; Greenbaum J; Schlom J; Greiner JW
    J Immunother; 1997 Nov; 20(6):449-59. PubMed ID: 9409450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
    Sampson JH; Archer GE; Ashley DM; Fuchs HE; Hale LP; Dranoff G; Bigner DD
    Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10399-404. PubMed ID: 8816812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
    Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
    Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: comparison of adenovirus- and retrovirus-mediated genetic transduction.
    Abe J; Wakimoto H; Yoshida Y; Aoyagi M; Hirakawa K; Hamada H
    J Cancer Res Clin Oncol; 1995; 121(9-10):587-92. PubMed ID: 7559742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of GM-CSF signaling in cell-based tumor immunization.
    Zarei S; Schwenter F; Luy P; Aurrand-Lions M; Morel P; Kopf M; Dranoff G; Mach N
    Blood; 2009 Jun; 113(26):6658-68. PubMed ID: 19282460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4.
    Wakimoto H; Abe J; Tsunoda R; Aoyagi M; Hirakawa K; Hamada H
    Cancer Res; 1996 Apr; 56(8):1828-33. PubMed ID: 8620500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.
    Salgia R; Lynch T; Skarin A; Lucca J; Lynch C; Jung K; Hodi FS; Jaklitsch M; Mentzer S; Swanson S; Lukanich J; Bueno R; Wain J; Mathisen D; Wright C; Fidias P; Donahue D; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Sugarbaker D; Mihm M; Dranoff G
    J Clin Oncol; 2003 Feb; 21(4):624-30. PubMed ID: 12586798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells.
    Yu JS; Burwick JA; Dranoff G; Breakefield XO
    Hum Gene Ther; 1997 Jun; 8(9):1065-72. PubMed ID: 9189764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines.
    Klein C; Bueler H; Mulligan RC
    J Exp Med; 2000 May; 191(10):1699-708. PubMed ID: 10811863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.
    Hodi FS; Schmollinger JC; Soiffer RJ; Salgia R; Lynch T; Ritz J; Alyea EP; Yang J; Neuberg D; Mihm M; Dranoff G
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6919-24. PubMed ID: 11983866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A; Hurwitz AA; Allison JP
    J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MCA106 fibrosarcoma cells transduced with granulocyte/macrophage colony-stimulating factor are not superior to the wild-type cells in suppressing the growth of hepatic metastases.
    Dong XD; Abdel-Wahab Z; Dematos P; Fong T; Pruitt SK; Seigler HF
    J Surg Oncol; 1999 May; 71(1):36-45. PubMed ID: 10362090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
    Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
    J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
    Stagg J; Wu JH; Bouganim N; Galipeau J
    Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
    Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
    Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.